胆固醇生物合成作为药物诱导的脆弱性在扩散大B细胞淋巴瘤不敏感的EZH2抑制
Rachele Niccolai1, Camiel Göbel1, Klevis Ndoj2
1Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Neoplasia (New York, N.Y.)
|October 28, 2025
概括
在扩散型大B细胞淋巴瘤中抑制EZH2揭示了对胆固醇生物合成的依赖. 针对这种途径使耐药癌细胞敏感,为耐EZH2的DLBCL提供了新的治疗策略.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症新陈代谢 癌症新陈代谢
- 淋巴瘤生物学的生物学
背景情况:
- 增强Zeste同源2 (EZH2) 是一个关键的表观遗传调节器在生殖中心B细胞类扩散大B细胞淋巴瘤 (GCB-DLBCL).
- GCB-DLBCL对EZH2抑制剂 (EZH2i) 具有可变的敏感性,因此需要采取克服耐药性的策略.
研究的目的:
- 为了确定EZH2抑制剂不敏感的GCB-DLBCL.在治疗上可利用的漏洞.
- 研究胆固醇代谢在EZH2抑制剂耐药性中的作用.
主要方法:
- 用EZH2抑制剂定CRISPR-Cas9脱落屏幕来识别重要的共同目标.
- 关于胆固醇吸收,低密度脂蛋白 (LDL) 受体表达和SREBP2激活的机制研究.
- 在体内异种移植模型评估治疗疗效.
主要成果:
- 胆固醇生物合成途径被确定为一个关键的共同目标,使EZH2i不敏感的GCB-DLBCL敏感.
- 抑制EZH2通过减少LDL受体表面表达和促进 lysosomal积累,损害了外源胆固醇的吸收.
- 减少的LDL吸收阻碍了补偿性胆固醇生物合成,使细胞对胆固醇生物合成抑制敏感.
结论:
- 胆固醇生物合成途径代表了EZH2抑制剂不敏感的GCB-DLBCL中的可针对性漏洞.
- 将EZH2抑制与胆固醇生物合成向结合起来,可能会改善耐药DLBCL的治疗结果.
- 对DLBCL患者的胆固醇抑制剂进行临床研究是有必要的,DLBCL患者对EZH2抑制无反应.
更多相关视频
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
6.5K
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11.5K
相关概念视频
01:29Cholesterol: Significance and Regulation
1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.2K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:31The Intrinsic Apoptotic Pathway
8.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.3K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K